Androgen News and Research

RSS

Homobrassinolide may increase appetite, muscle mass and physical performance

New research in The FASEB Journal suggests that rats fed homobrassinolide, found in the mustard plant, produced an anabolic effect, and increased appetite and muscle mass, as well as the number and size of muscle fibers.

30 Sep 2011

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to results from a phase III clinical trial presented today.

26 Sep 2011

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron Pharmaceuticals, Inc. today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

26 Sep 2011

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival.

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

LA BioMed andrologist leads new male contraceptive Phase I clinical study

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) - one of the leading biomedical research institutes in the country - is currently working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent.

20 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

Animals burn protein during long, cold hibernation

When Arctic ground squirrels are getting ready to hibernate they don't just get fat - they pack on muscle at a rate that would make a bodybuilder jealous. And they do it without suffering the harmful effects that high levels of testosterone and other anabolic steroids usually cause. University of Toronto Scarborough (UTSC) researchers have started to untangle how the squirrels manage it, and their results could someday have implications for human health.

16 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

Biologists reveal why men's ring fingers are longer than their index fingers

Biologists at the University of Florida have found a reason why men's ring fingers are generally longer than their index fingers - and why the reverse usually holds true for women.

6 Sep 2011

Sex hormones strongly influence people's interests in occupations

Teacher, pilot, nurse or engineer? Sex hormones strongly influence people's interests, which affect the kinds of occupations they choose, according to psychologists.

2 Sep 2011

A CRADA for prostate disease research

Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.

22 Aug 2011

Inherited genetic links to prostate cancer discovered

Researchers from the U.S. and Sweden have linked five inherited genetic mutations to the development of a particularly aggressive and deadly form of prostate cancer. They suggest that these findings could someday lead to development of an easy-to-administer blood test to screen for such mutations to help physicians assess the long-term risk faced by newly diagnosed prostate cancer patients.

17 Aug 2011

Researchers identify five SNPs linked with aggressive, lethal prostate cancer

An international team of researchers led by Fred Hutchinson Cancer Research Center has identified five inherited genetic variants that are strongly associated with aggressive, lethal prostate cancer.

17 Aug 2011

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer.

10 Aug 2011

GTx reports revenue of $1.6 million for second quarter 2011

GTx, Inc. today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010.

9 Aug 2011

PCF funds 10 new Challenge Awards for prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 10 new Challenge Awards for accelerating scientific discovery and new treatments for prostate cancer patients.

5 Aug 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis Pharmaceuticals Corporation announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

21 Jul 2011